ERS/EULAR结缔组织病相关间质性肺病临床实践指南
欧洲呼吸学会与欧洲抗风湿病联盟组成多学科工作组,基于PICO问题和GRADE方法制定结缔组织病相关间质性肺病(CTD-ILD)的筛查、诊断、治疗和随访推荐。针对系统性硬化、类风湿关节炎、特发性炎性肌病、干燥病、系统性红斑狼疮和混合性结缔组织病共形成25个PICO和28个叙述性问题的推荐,并开发了相关算法。许多情况下证据确定性低或缺乏,工作组鼓励进一步研究填补空白。
要点
- 指南覆盖系统性硬化、RA、特发性炎性肌病、干燥病、SLE和MCTD相关ILD的筛查、诊断、监测与治疗。
- 基于GRADE方法形成25个PICO和28个叙述性问题的推荐,并开发了临床算法。
- 部分问题(如MCTD、干燥病和SLE的筛查与进展风险评估,以及非RA-ILD的吡非尼酮)证据不足未形成推荐。
核心结论
- 工作组为每种结缔组织病提供了基于证据的实用推荐,涵盖CTD-ILD的筛查、诊断、监测和治疗。
- 许多情况下证据确定性低或缺乏,工作组鼓励进一步研究以填补证据空白。
研究设计与样本
- 欧洲呼吸学会和欧洲抗风湿病联盟工作组由呼吸科医生、风湿科医生、病理科医生、放射科医生、方法学家和患者代表组成。
- 基于PICO问题,采用GRADE方法分级证据,并结合两学会商定的补充叙述性问题,使用Evidence to Decision框架制定推荐。
主要发现
- 工作组针对系统性硬化、类风湿关节炎(RA)、特发性炎性肌病、干燥病(SjD)、系统性红斑狼疮(SLE)和混合性结缔组织病(MCTD)相关ILD形成25个PICO和28个叙述性问题的推荐。
- 在4个关于MCTD、SjD和SLE的ILD筛查和进展风险评估的叙述性问题,以及1个关于非RA-ILD的CTD-ILD使用吡非尼酮的PICO问题上,证据不足未形成推荐。
临床怎么用
- 临床医生可参考该指南对每种结缔组织病相关ILD进行筛查、诊断、监测和治疗决策。
- 指南提供了基于推荐和常规临床实践开发的筛查、诊断、监测和治疗算法。
局限性
- 许多情况下证据确定性低或缺乏,部分临床问题无法形成推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interstitial lung disease (ILD) is a frequent manifestation of connective tissue diseases (CTDs) and is associated with high morbidity and mortality. Clinical practice guidelines to standardise screening, diagnosis, treatment and follow-up for CTD-ILD are of high importance for optimised patient care. METHODS: A European Respiratory Society and European Alliance of Associations for Rheumatology task force committee, composed of pulmonologists, rheumatologists, pathologists, radiologists, methodologists and patient representatives, developed recommendations based on PICO (Patients, Intervention, Comparison, Outcomes) questions with grading of the evidence according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology and complementary narrative questions agreed on by both societies. For both PICO and narrative questions, the Evidence to Decision framework was used to formulate the recommendations. RESULTS: The task force committee concluded with recommendations for 25 PICO and 28 narrative questions, regarding ILD in the context of systemic sclerosis, rheumatoid arthritis (RA), idiopathic inflammatory myopathies, Sjögren disease (SjD), systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD). In four narrative questions, regarding screening and assessment of risk for ILD progression in MCTD, SjD and SLE and one PICO question regarding pirfenidone in CTD-ILD other than RA-ILD, the task force had insufficient evidence to support recommendations. Screening, diagnostic, monitoring and treatment algorithms were developed based on the recommendations and usual clinical practice. CONCLUSIONS: We provide practical guidance by evidence-based recommendations to clinicians for each of the CTDs. In many cases there is low certainty or absence of evidence and we encourage further research to fill these gaps.
引用
- Antoniou KM, Distler O, Gheorghiu AM, et al. ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease. Eur Respir J. 2026. PMID: 40907995. doi:10.1183/13993003.02533-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。